Cargando…

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound...

Descripción completa

Detalles Bibliográficos
Autores principales: Koster, Kira-Lee, Huober, Jens, Joerger, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400777/
https://www.ncbi.nlm.nih.gov/pubmed/36046357
http://dx.doi.org/10.37349/etat.2022.00069
_version_ 1784772816389799936
author Koster, Kira-Lee
Huober, Jens
Joerger, Markus
author_facet Koster, Kira-Lee
Huober, Jens
Joerger, Markus
author_sort Koster, Kira-Lee
collection PubMed
description Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound to a potent cytotoxic agent (the payload), via a linker, contributing to an improved therapeutic index. Currently, three ADCs received approval by the US Food and Drug Administration (FDA) and are in routine clinical use in different treatment settings; many more ADCs are in earlier and later stages of development, and their future approval will improve treatment options for patients with advanced but potentially also early-stage BC over time. Just recently, the results of three phase 3 trials (ASCENT, TULIP, and DESTINY-Breast03) evaluating sacituzumab govitecan (SG), trastuzumab duocarmazine, and trastuzumab deruxtecan (T-DXd) in different treatment settings were presented and showed promising results. This overview focuses on the newer ADCs, including T-DXd and SG, their pharmacology, mechanisms of action, and relevant studies. In addition, the latest results from trials investigating some newer ADCs, in further stages of development are presented.
format Online
Article
Text
id pubmed-9400777
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Open Exploration
record_format MEDLINE/PubMed
spelling pubmed-94007772022-08-30 New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development Koster, Kira-Lee Huober, Jens Joerger, Markus Explor Target Antitumor Ther Review Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that combines an antigen-specific antibody backbone bound to a potent cytotoxic agent (the payload), via a linker, contributing to an improved therapeutic index. Currently, three ADCs received approval by the US Food and Drug Administration (FDA) and are in routine clinical use in different treatment settings; many more ADCs are in earlier and later stages of development, and their future approval will improve treatment options for patients with advanced but potentially also early-stage BC over time. Just recently, the results of three phase 3 trials (ASCENT, TULIP, and DESTINY-Breast03) evaluating sacituzumab govitecan (SG), trastuzumab duocarmazine, and trastuzumab deruxtecan (T-DXd) in different treatment settings were presented and showed promising results. This overview focuses on the newer ADCs, including T-DXd and SG, their pharmacology, mechanisms of action, and relevant studies. In addition, the latest results from trials investigating some newer ADCs, in further stages of development are presented. Open Exploration 2022 2022-02-24 /pmc/articles/PMC9400777/ /pubmed/36046357 http://dx.doi.org/10.37349/etat.2022.00069 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Koster, Kira-Lee
Huober, Jens
Joerger, Markus
New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
title New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
title_full New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
title_fullStr New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
title_full_unstemmed New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
title_short New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
title_sort new antibody-drug conjugates (adcs) in breast cancer—an overview of adcs recently approved and in later stages of development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400777/
https://www.ncbi.nlm.nih.gov/pubmed/36046357
http://dx.doi.org/10.37349/etat.2022.00069
work_keys_str_mv AT kosterkiralee newantibodydrugconjugatesadcsinbreastcanceranoverviewofadcsrecentlyapprovedandinlaterstagesofdevelopment
AT huoberjens newantibodydrugconjugatesadcsinbreastcanceranoverviewofadcsrecentlyapprovedandinlaterstagesofdevelopment
AT joergermarkus newantibodydrugconjugatesadcsinbreastcanceranoverviewofadcsrecentlyapprovedandinlaterstagesofdevelopment